Clearing US biosimilar pathway hurdles is expected to be an arduous exercise

Published: 2010-04-19 07:00:00
Updated: 2010-04-19 07:00:00
Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry.

On March 23, 2010, President Obama signed into law healthcare reform legislation known as the “Patient Prot...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.